TBA (last known deadline was October 15, 2012)
Applications are solicited to evaluate the therapeutic potential of CDK4/6 inhibition in melanoma. Proposals evaluating biomarkers of response to CDK4/6 inhibition, interactions with dysregulated signaling pathways such as MAPK, combinatorial treatment regimens, and efficacy in treating or preventing resistance to agents targeting signaling pathways or immunologically relevant molecules, are encouraged.
A letter of support from Pfizer is required at the time of application. All “letters of intent” for planned research proposals should be sent to Pfizer at its web portal located at www.pfizer.com/iir with “MRA” clearly stated in the title. Please refer to information on MRA Academic-Industrial Partnership Awards for other application requirements and grant terms and conditions.